Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNFerade with Chemoradiation for Rectal Cancer
NCT00137878Phase 2Completed
- Sponsor
- GenVec
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of golnerminogene pradenovec in rectal cancer (2 arms), sponsored by GenVec. Primary endpoint: Pathologic Complete Response. Status: completed.
02
Drugs
golnerminogene pradenovec
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00137878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00137878.